Latest Modus Therapeutics News & Updates

See the latest news and media coverage for Modus Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Modus Therapeutics

Swedish biotechnology company developing sevuparin

modustx.com

Headquarters: Stockholm, Sweden
Founded year: 2011
Company type: Public company
Number of employees: 5–10

Last updated Today

Latest news about Modus Therapeutics

In short: Modus Therapeutics progressed its clinical and preclinical research for sevuparin while securing significant funding through several rights issues.

Company announcements

June 18 Modus Therapeutics

Modus Therapeutics announces SEVUSMART manuscript preprint

The Phase Ib study evaluates sevuparin in children with severe malaria, led by Prof. Kathryn Maitland at Imperial College London.

May 28 Modus Therapeutics

Modus Therapeutics announces decisions from its Annual General Meeting

The AGM resolved no dividend, discharged board and MD, re-elected Viktor Drvota, elected Pernilla Sandwall and Sofi Eriksson, approved SEK110,000 fees, reappointed Ernst & Young, and authorized share issues.

May 25 Modus Therapeutics

Modus Therapeutics publishes interim report for Q1 2026

The report highlights disciplined execution and progress in the Phase IIa study for sevuparin, with proof-of-concept readout expected by end of 2026.

April 27 Modus Therapeutics

Modus announces outcome of TO 2026 warrants exercise

The exercise rate is 94.8%, yielding approximately SEK 9.5 million before costs and 18% dilution.

Media coverage

May 26 Morningstar

Modus Therapeutics advances sevuparin study in chronic kidney disease with anemia - PharmaTimes

Proof-of-concept phase begins with first patient enrolled...

Never miss news about Modus Therapeutics

Track Modus Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.